Market News

As part of the approval, Teva has agreed to the divestment of certain overlapping molecules in 24 European countries.

The company has officially opening its second office, which is dedicated to the support of the ongoing and future projects for business partners from the West Coast of US.

Collaboration will use Siteseeker — a new ‘phenotypic’ screening platform that exploits the dynamics of a live-cell environment to uncover hidden druggable target sites across the entire human genome — to find new therapeutic options.

FDA requested additional CMC information for the Multi-Dose Preservative-Free bottle.

Acquisition enhances Lupin’s scale in the US generic market and broadens Lupin’s pipeline in dermatology, controlled substance products and other high-value and niche generics.

Facility being operated by Avid Bioservices subsidiary with capacity to potentially generate additional $40 million in annual revenue.

Dr Anders Lonner has stepped down as a director due to other priorities and personal commitments.

Used to demonstrate the use of statistical methodologies of Principal Components Analysis and Design of Experiments.

Instrument of the Year for Thermo Scientific Dionex Ion Chromatography portfolio.

The investment will enable higher throughput of samples, and electronic data capture to ensure integrity of information in regulatory submission and acceptances.

The two companies will pursue their own distinct growth strategies.

This specially designed facility has internationally recognized certification for the containment and safe handling of Level II and Level IV APIs, and will provide customer’s faster turnaround on technical services and increased capacity to handle more...

With these new investments, Grifols increases its production capacity to continue covering the expected growing demand in the plasma-derived products until 2028–2030.

GBI Research says the pipeline may significantly alter the clinical and commercial landscape of the disease market over the next decade.

Acquisition will strengthen McKesson's position in Canada's pharmaceutical supply chain.

The launch represents a a key milestone on the company's path to secure new product approvals from the FDA.

Certified quality of analytical services for developers of biologics and biosimilars .

Acticor Biotech is developing an antibody fragment (Fab) considered as a first-in-class anti-thrombotic agent without bleeding risk in the primary treatment of ischemic strokes.

Blueberry Therapeutics is set to create safe, effective “nanomedicines” to treat a number of unmet clinical needs.

The company plans to introduce the new brand to its 43,000 employees around the world prior to launching the brand externally.

Chem-space.com online searchable marketplace features over 15 million compounds.

Moventig is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) approved in Europe for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s).

J. Michael Pearson to return as CEO following illness, effective immediately.

GBI Research report says that despite steady market growth, various unmet needs remain and a cure is yet to be found.

Analysis, trends and opportunities report 2016–2020 — key vendors: General Electric, Pall Corporation, 3M.

Cobra and CPI will develop in depth scientific and technical understanding to allow a scalable and flexible manufacturing process to be developed to produce, purify and characterise a range of AAV vectors.

Acquired site manufactures enzyme-based fermentation products and intermediates for the pharma industry.

£22 million investment in Liverpool by global biopharma company.

SigNature DNA offers authenticity and traceability for pharmaceutical global supply chains.

Retrofit ensures long-term process reliability.

BalanCD CHO Feed 4 is a chemically-defined, animal component-free powder feed for large-scale bioproduction in a variety of high performing CHO cells.

Agreement will leverage both Bespak and Aesica capabilities.

Adds an important technology in the filling of injectable beta lactams with sales to the US and European markets.

Valid Insight’s launch aims to meet the market access challenges facing new medicines, helping life science research to translate into real-world benefits for patients and society.

The agreements with ViiV Healthcare do not impact BMS’s marketed HIV medicines, including Reyataz, Evotaz, Sustiva and Atripla.

FDA provides GDUFA goal date of 28 March 28 2017

Alliance to provide drug discovery customers access to industry leading ion channel and transporter technologies.

The first and only buprenorphine formulation developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management.

Dublin headquarters central to European and global growth strategy.

Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma.

Expansion reflects critical role of MSD’s Irish sites in wider global network.

The acquisition of InvaGen Pharmaceuticals provides Cipla with about 40 approved ANDAs, 32 marketed products, and 30 pipeline products which are expected to be approved during the next 4 years.

Athenex to invest $1.62 billion in drug discovery and advanced manufacturing partnership, creating 900 jobs in Dunkirk and 500 jobs in Buffalo during the next 10 years.

Patent protects the composition of Rizaport and will be listed in the Orange Book upon approval of the product by FDA.

Designed for use in biotechnological applications, especially for membrane screening and small-volume process development.

Lilly plans to seek permission to appeal the ruling.

Leading CDMO is granted both the WorldStar Award for Vetter-Ject and a 2016 CMO Leadership Award.

Symbiosis Pharmaceutical Services has picked-up several new clients in North America, which has primarily been driven by companies looking for small-scale aseptic manufacturing capabilities to support clinical trials.

Compatibility and testing of nested container and closure systems to help pharmaceutical companies manufacture parenteral medicines.

Combining ThioLogics' site-specific conjugation chemistry with Albumedix's drug delivery platform enables the creation of next-generation albumin drug conjugates.

Responding to the needs of users in the laboratories, Sartorius presents a new range of mechanical pipettes with a perfectly balanced design offering reliability, accuracy and comfortable use.

Pneumatic-powered bottling pick-up grab heads for use with major lines of new or replacement bottling machinery.

Deal strengthens Novartis immunology portfolio which includes investigational biosimilars adalimumab, etanercept and rituximab.

The CMA has fined a number of pharmaceutical companies for anti-competitive conduct and agreements in relation to the supply of paroxetine.

The acquisition allows the company to effectively expand its global presence from operating sites in Japan, Spain, Romania, Canada and the US, to include Brazil.

Practical trainings on globally trending topics.

These meetings will cover aspects of pharmaceutical cleanroom sporicidal disinfection and environmental monitoring best practice during manufacture of pharmaceuticals.

The serialisation of licensed drug products will be a legal requirement for companies in the EU from early 2019.

The pay-for-performance agreement ties the financial terms to how well the drug improves the relative health of Cigna's customers.

Multi-year R&D collaboration with AbbVie focused on novel medicines for treatment of inflammatory bowel disease.

Pfizer will continue to manage its commercial operations through two distinct businesses — the innovative products business and the established products business — after the completion of the proposed transaction.

Genevac Series 3 HT Evaporator developed to provide a rapid, high-throughput alternative to freeze drying HPLC purification fractions.

MedinCell and Sandoz will develop and commercialize long-acting injectable products based on BEPO technology with a primary focus on oncology.

Using its established development platform and unique expertise in virology, Microbix intends to develop and launch a range of products to help combat the Zika virus.

Global API market driven by the rising abbreviated new drug applications and the growth in filing drug master files from several Indian firms, says Transparency Market Research.

The initial laboratory space will amount to 5,500 sq. ft, which constitutes nearly 20% increase in Selvita laboratory space, compared to the current state with significant extension possibilities.

The collaboration will use Exaxion's computer-based technology to discover novel antigens.

EMA approves Merck's GONAL-f prefilled pen 2.0.

These guidelines primarily focus on recommendations for systems for manufactures of solid dosage forms.

Agreement further supports Teva’s novel biologics development program.

Genentech has won the Process Innovation category for its large-scale, Cell Culture Biologics Drug Substance Plant 2 (CCP2) located in Vacaville, CA.

Price concerns regarding sustainable coatings will be countered by their environmental and durability benefits, finds Frost & Sullivan.

Annual ‘Drugs to Watch’ study spotlights seven emerging blockbusters poised to enter the market in 2016.

The CDMO will also manufacture 20,000 capsules of the reformulated monepantel solution for the Australian company

Singapore site now provides full clinical supply services.

Capabilities will focus on parenteral dosage forms for biologics, drug conjugates, peptides and small molecules for products for injection or infusion.

Building on the company's successful history in developing vaccines against similar viruses, most recently the introduction of Dengvaxia against dengue, Sanofi Pasteur is launching a Zika vaccine project.

Andexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban).

Thermo Scientific Environmental Chambers use a unique airflow system for advanced temperature control.

The new research space will add 15,000 sq.ft. to Aragen’s existing laboratories and will double capacity for diverse efficacy studies.

Imatinib mesylate is the therapeutic equivalent to Novartis's Gleevec for indications approved by FDA.

This new collaboration will enhance the mission to provide a comprehensive platform to enable the growth of a quality African pharmaceutical industry that competitively contributes to the healthcare needs of Africans.

ATM-AVI is an investigational, fixed-dose antibiotic combining aztreonam and avibactam.

Several projects will be studied to further develop existing local manufacturing collaborations and work on programs to fight chronic and non-communicable diseases.

Additional space will primarily be used to increase laboratory facilities, GMP suites and allocate space for storage of GMP materials.

Agreement for Plendil in China reinforces AstraZeneca’s focus on innovative medicines.

Gary Zieziula to head biopharma business in North America and Marc Horn to lead biopharma business in China.

This award recognizes the company with the highest reviews and ratings on SelectScience.

Redipor prepared media to be supplied directly to customers.

Company to focus on pipeline of Pentarins as a unique and promising approach to treating solid tumour cancers.

Transparency Market Research has announced the publication of a new report, titled "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020".

New website will support clients in developing and implementing entire single-use bioprocesses.

Albumedix strengthens its leading position in albumin-based drug delivery through acquisition of Eleven's Supermin albumin technology.

The new stand-alone company Albumedix will continue to develop albumin-based products and technologies for the pharmaceutical industry.

Recombinant Fc Receptor proteins from AMSBIO are uniquely suitable for pharmaceutical research.

The addition of the Paulaur products complements Colorcon’s Suglets Sugar Spheres product line and enhances Colorcon’s position as a leading global supplier of sugar spheres for the development of multiparticulate dosages.

The addition of Kalbitor and DX-2930 to Shire's portfolio strengthens its leadership position in hereditary angioedema.

The ideal solution for scaling studies and low volume ultra- and diafiltration operations.

Payer relationship activities are especially important to start early, according to Cutting Edge Information.

A new Consumer Health brand for gastrointestinal upset, starting in January 2016 with Chile.

With the sophisticated developments in microneedle patches, injectors and pre-filled syringes come increasing opportunities for using liquid silicone rubber.

The Chronic Obstructive Pulmonary Disease (COPD) treatment pipeline lacks innovation despite an influx of new therapies, says GBI Research.

The introduction of KANEKA KanCapA expands the portfolio of continuous bioprocessing and chromatography products offered by Pall.

The facility will provide full-service solutions, including project management and clinical supply management, comparator sourcing, secondary packaging and labeling, clinical storage, distribution, and drug return and destruction.

Recommended for monotherapy or adjunctive therapy in the treatment of partial seizures.

Testing services for cosmeceuticals, natural health products and medical marijuana from facilities in Canada.

Kuehne + Nagel to run the core business of transporting products from the raw materials supplier to trade customers for the leading global healthcare company.

New improved antibody oligonucleotide conjugation kit.

Company has acquired Alphamer immuno-therapeutics platform technology.

Court says MSD breached an agreement with Merck by using "Merck" alone either as a trade mark or a name in the UK.

Biogen will manufacture and commercialize Benepali in the EU.

Patient-focused models, improving adherence, and controlling costs all benefit from TD3.

Frost & Sullivan Partner Dorman Followwill comments on one of the disrupting forces that are transforming the healthcare markets.

The deal is based on milestone payments during 2016 and royalty payments per sold dose. Product launch is expected during 2017.